PDF
(Download)
|
- Hibiscus (Hibiscus sabdariffa)
- Dyslipidemia
- Obesity
|
Date:
12-13-2013 | HC# 111361-486
|
Re: Hibiscus Supplementation May Be Effective in Adolescents with Dyslipidemia
Sabzghabaee AM, Ataei E, Kelishadi R, et al. Effect of Hibiscus sabdariffa calices [sic] on dyslipidemia in obese
adolescents: a triple-masked randomized controlled trial. Mater Sociomed. 2013;25(2):76-79.
Dyslipidemia,
or atypical lipid concentrations, is often seen in those suffering from obesity
and is associated with a higher risk for cardiovascular disease (CVD). It is
thought that addressing obesity and CVD risk factors in adolescents may prevent
future health problems. Hibiscus (Hibiscus
sabdariffa) is traditionally used in Iran and has been shown to have broad
bioactivity. This randomized, triple-blind, placebo-controlled trial
investigated effects of hibiscus supplementation in obese Iranian adolescents.
This
study took place at the Isfahan Cardiovascular Research Institute, Isfahan,
Iran, and enrolled 90 adolescents from 12-18 years old. Patients had serum
triglyceride, total cholesterol, and low-density lipoprotein (LDL)
concentrations greater than the 90th percentile, high-density
lipoprotein (HDL) concentrations less than the 10th percentile
(percentile demographic is not defined), did not consume tobacco, alcohol, or
drugs, did not have diabetes, thyroid, or other organ problems, and were not using
pharmaceuticals that impacted lipid concentrations or hormones. Those that did
not adhere to compliance, were pregnant or lactating, had sensitivity to drugs,
or had health problems affecting lipid concentrations or necessitating drugs
impacting lipids were excluded.
At
baseline, patients had lipid concentrations, fasting blood glucose, and thyroid
hormone measured. Lipid concentrations were also measured at the end of the
study. Diet and exercise were standardized, and patients received counseling
from a registered dietitian. Hibiscus was procured at a market in Isfahan,
Iran, and calyces were dried and powdered. The amount of polyphenols of the
powder was determined to be 16.4 mg gallic acid per gram. Treatment consisted
of 6 g of powdered hibiscus or placebo in divided doses for 4 weeks. Placebo was
not specified. Metabolic measurements were also taken at the end of the study.
From
the 90 patients enrolled in the study, 43 were randomly assigned to the
treatment group, and 47 were randomly assigned to the control group. From
these, 7 in the treatment group and 11 in the control group were dropped from
the study because of pharmaceutical use, diet changes, or lipid measurement
inconsistencies. In total, 36 patients in each group completed the study with
an average age of 14.17 ± 1.61 years in the treatment group and 14.25 ± 1.59
years in the control group. There were no significant differences in average
age, gender, body mass index, or lipid profiles at baseline between groups.
Following
treatment with hibiscus, total cholesterol was significantly decreased from
186.5 ± 30.42 mg/dl at baseline to 176.11 ± 23.1 mg/dl at endpoint (P=0.003).
Those in the treatment group also had a significant decline in triglyceride
concentrations (134.22 ± 50.17 mg/dl vs. 146 ± 49.87 mg/dl at baseline,
P=0.022). LDL concentrations significantly decreased in the treatment group at
the end of the study as compared to baseline measurements (103.36 ± 21.94 mg/dl
vs. 111.36 ± 24.54 mg/dl, P<0.001). Although not significant, HDL
concentrations also decreased in this group (43.17 ± 7.77 mg/dl vs. 45.64 ±
8.59 mg/dl at baseline, P=0.057). No differences in any of these parameters were
observed in the control group; however, the decline in triglyceride
concentrations of the control group approached significance as compared to
baseline (166.17 ± 44.42 mg/dl vs. 163.44 ± 43.64 mg/dl, P=0.052). The adverse
side effect reported was "temporary constipation."
In
summary, this study shows that hibiscus supplementation significantly modulated
triglyceride and LDL concentrations in obese adolescents. A larger sample size
is needed to differentiate the potential effects of hibiscus consumption on
triglyceride concentrations as decreases were also observed in the control
group. The decrease in HDL concentration with hibiscus treatment approached
significance and should be addressed in future studies. Also, the triple-blinded
methodology is not described, and it is suggested that the study duration
should be longer in future trials. Despite these shortcomings, hibiscus supplementation
may be an effective therapy to address dyslipidemia in obese adolescents.
—Amy C. Keller,
PhD
|